# Safety and Efficacy of ADDERALL XR in the Treatment of Adolescents Aged 13-17 With Attention Deficit Hyperactivity Disorder (ADHD)

> **NCT00507065** · PHASE3 · COMPLETED · sponsor: **Shire** · enrollment: 329 (actual)

## Conditions studied

- ADHD

## Interventions

- **DRUG:** Mixed salts of a single-entity amphetamine (ADDERALL XR)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00507065
- **Lead sponsor:** Shire
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-05-28
- **Primary completion:** 2004-03-24
- **Final completion:** 2004-03-24
- **Target enrollment:** 329 (ACTUAL)
- **Last updated:** 2021-06-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00507065

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00507065, "Safety and Efficacy of ADDERALL XR in the Treatment of Adolescents Aged 13-17 With Attention Deficit Hyperactivity Disorder (ADHD)". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00507065. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*